title: Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia.
abstract: Acute promyelocytic leukemia (APL) is uniquely sensitive to treatment with all-trans retinoic acid (ATRA) which exerts its action via a well-documented cytodifferentiating mechanism. The combination of this retinoid with anthracyclines gives high percentages of complete remission and is now considered the optimal induction treatment for APL patients. Continuous treatment with ATRA, however, induces accelerated drug catabolism, with progressive decline in plasma drug concentrations potentially to below the levels required to maintain differentiation of leukemic cells. This process, which occurs rapidly and consistently has led to the hypothesis that the development of acquired clinical resistance to ATRA in APL has a pharmacologic basis. The rapid autoinduction of the hypercatabolic state precludes maintenance with continuous ATRA oral dosing, and is a limitation of better use of the drug both in APL and in other disorders in which it could be beneficial. Here we briefly review the pharmacologic alterations of ATRA metabolism induced by continuous oral administration, the clinical implications of this phenomenon, and the strategies currently under investigation to prevent or overcome the induced catabolism of this retinoid.
authors.affiliation: Institute of Hematology, University of Pavia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Lazzarino
authors.forename: M B
authors.initials: MB
authors.lastname: Regazzi
authors.forename: A
authors.initials: A
authors.lastname: Corso
mesh_terms: D000284:Administration, Oral; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000378:metabolism*; D008081:Liposomes; D014212:Tretinoin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D008081:Liposomes; D014212:Tretinoin